Abstract: The Agastache rugosa extract or the isoagastachoside or crude polysaccharide fraction included in the extract according to the present invention can be prepared based on plants being domestically cultivated, and thus is advantageous in terms of time and cost, and can effectively inhibit the differentiation, growth, and bone resorption functions of osteoclast progenitor cells, thus increasing bone density and the like, and accordingly, can be effectively used for the prevention, amelioration, or treatment of diseases related to bone loss caused by differentiation into osteoclasts or excessive activity of osteoclasts. In addition, the active ingredient, which is a plant-derived natural substance, is safe due to fewer side effects on the human body compared to chemical drugs, and inhibits osteoclast progenitor cells independently of estrogen, and thus can be widely used in osteoporosis occurring due to various causes other than menopause.

Abstract: The present invention relates to a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases, containing a maple leaf extract as an active ingredient. The maple leaf extract exhibits an effect of inhibiting hyperemia in the eyeball in which hyperemia has been induced and an effect of inhibiting angiogenesis in the eyeball in which corneal damage has been induced, thus being effectively used in a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases.

Abstract: The present invention relates to a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases, containing a maple leaf extract as an active ingredient. The maple leaf extract exhibits an effect of inhibiting hyperemia in the eyeball in which hyperemia has been induced and an effect of inhibiting angiogenesis in the eyeball in which corneal damage has been induced, thus being effectively used in a pharmaceutical composition for preventing and treating corneal diseases or conjunctival diseases.

Abstract: A gel-type bird aversion composition consists of, on the basis of weight, 30 to 90% of a thickening agent, 0.01 to 4% of an ultraviolet ray absorbent, 0.1 to 20% of methyl anthranilate, 0.1 to 10% of cinnamon essential oil, 0.1 to 20% of mint essential oil; 5 to 40% by weight of mineral oil or grease; and 1 to 10% by weight of emulsifier.

Abstract: A gel-type bird aversion composition consists of, on the basis of weight, 30 to 90% of a thickening agent, 0.01 to 4% of an ultraviolet ray absorbent, 0.1 to 20% of methyl anthranilate, 0.1 to 10% of cinnamon essential oil, 0.1 to 20% of mint essential oil; 5 to 40% by weight of mineral oil or grease; and 1 to 10% by weight of emulsifier.